Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
Conditions: Advanced Cancer; Advanced Malignancies; Bladder Cancer; Cervical Cancer; Esophageal Cancer; Gastric Cancer; Gastroesophageal-junction Cancer (GEJ); Head and Neck Squamous Cell Carcinoma (HNSCC); Non-Small Cell Lung Cancer (NSCLC); Ovarian Cancer; Renal Cell Carcinoma (RCC); Triple Negative Breast Cancer (TNBC) Interventions: Drug: AB598; Drug: Zimberelimab; Drug: Carboplatin; Drug: Pemetrexed; Drug: Fluorouracil; Drug: Leucovorin; Drug: Oxaliplatin Sponsor: Arcus Biosciences, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Alimta | Cancer | Cancer & Oncology | Carcinoma | Eloxatin | Gastroenterology | HNSCC | Non-Small Cell Lung Cancer | Research | Study